ArticleCureus2026
Neuropsychiatric Presentation of Non-paraneoplastic Voltage-Gated Calcium Channel Autoimmune Encephalitis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune encephalitis is an immune-mediated inflammatory disorder of the brain with diverse neurological and psychiatric manifestations. Voltage-gated calcium channel (VGCC) antibody-associated autoimmune encephalitis is rare and has been predominantly described in paraneoplastic settings. Emerging reports suggest a broader range of central nervous system involvement, but presentations dominated by psychiatric symptoms remain uncommon and diagnostically challenging. A 39-year-old man with no prior medical illness presented with subacute progressive cognitive decline, behavioral changes, and religious-themed complex auditory hallucinations over three to four months. Initial evaluation, including magnetic resonance imaging, electroencephalography, and standard autoimmune encephalitis antibody testing, was unrevealing. Extended cerebrospinal fluid and serum autoimmune testing were done, which demonstrated elevated VGCC antibody levels. Comprehensive malignancy screening, including whole-body positron emission tomography, showed no evidence of an underlying neoplasm. The patient showed partial improvement following intravenous methylprednisolone and intravenous immunoglobulin (IVIG). Symptom recurrence necessitated repeat IVIG and escalation to rituximab therapy, resulting in sustained clinical improvement. This case broadens the recognized clinical spectrum of VGCC antibody-associated autoimmune encephalitis by highlighting a presentation dominated by psychiatric symptoms in the absence of malignancy or classical neurological features. Recognition of such atypical presentations is essential, as early diagnosis and appropriate immunotherapy can lead to favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.